# PE-PE: HCP commentary report

> 35 verified statements (24 from clinicians verified by NPI or staff page) from 13 commentary sources · 6 findings · updated Oct 29, 2026

## Report

- Trial: Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer. (The PE-PE Study).
- NCT ID: NCT05578664
- Registry: https://clinicaltrials.gov/study/NCT05578664
- Sponsor: Consorzio Oncotech
- Phase: Phase 2
- Status: Active, not recruiting
- Drugs tested: pembrolizumab
- Indication: oligometastatic renal cell carcinoma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-29
- Last checked: 2026-10-29
- Release hash: d5bb971a8cb6cdbed88a42b0abb3c335e0504e1cc0f08c6fdc81a827717574c7

## Counts

- HCP commentary sources screened: 30
- Sources cited by verified statements: 14
- Verified statements: 35
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 24
- Findings: 6
- Named people in screened sources (unnamed speakers and accounts not counted): 14
- Voices cited: 14
- Cited voices identity-verified: 13
- Organisational or shared accounts (not counted as people): 1

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

PE-PE asks whether adding pembrolizumab to metastasis-directed surgery or radiotherapy delays relapse in oligometastatic clear-cell kidney cancer. An X poster supports addition but questions sequencing, while an X poster describes systemic-treatment deferral as selective. An X poster welcomes the randomized question yet regards overall-survival and quality-of-life benefits as unresolved. Local-treatment technique and disease history remain questions raised on X. The sources place PE-PE’s phase II results at ESMO 2026.

## Open Medical Affairs question

Which PE-PE-like patients warrant added systemic treatment, and when is MDT-first deferral reasonable given toxicity and unestablished survival or quality-of-life benefit?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Support for adding pembrolizumab is stronger than the evidence for survival, quality of life or treatment-component synergy
- F2. MDT-first systemic-treatment deferral is described as a selective exception
- F3. The favorable RFS reading carries a meaningful toxicity qualification
- F4. The oligometastatic definition and recurrence interval determine what clinicians regard as new
- F5. Radiation inclusion is valued, but adjuvant intent and the pre-MDT dose remain separate questions
- F6. Distant relapse supports a systemic-treatment rationale, while technical details remain important to interpretation

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 13 | 8 | 6 | 6 | none recorded | 3 |
| F2 | 2 | 2 | 2 | 2 | none recorded | 3 |
| F3 | 6 | 5 | 5 | 5 | none recorded | 3 |
| F4 | 9 | 8 | 6 | 6 | none recorded | 4 |
| F5 | 8 | 7 | 4 | 5 | none recorded | 3 |
| F6 | 5 | 2 | 2 | 2 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 7 | 0 | 1 | 0 | 5 | 14 | 1 | 5 posts and articles, 1 registry | yes |
| F2 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 2 posts and articles | yes |
| F3 | 3 | 0 | 0 | 0 | 3 | 6 | 0 | 5 posts and articles | yes |
| F4 | 4 | 2 | 0 | 1 | 2 | 9 | 0 | 5 posts and articles, 1 registry | yes |
| F5 | 2 | 2 | 0 | 1 | 3 | 8 | 1 | 3 posts and articles, 1 registry | yes |
| F6 | 2 | 2 | 0 | 0 | 1 | 5 | 0 | 2 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Relapsed Free Survival (RFS): F1 (5 shared claims), F3 (4 shared claims), F6 (2 shared claims)
- Secondary endpoint: Distant Relapsed Free Survival (Distant RFS): F3 (1 shared claims), F6 (3 shared claims)
- Secondary endpoint: Overall Survival (OS): F1 (1 shared claims), F3 (2 shared claims), F6 (1 shared claims)
- Secondary endpoint: Safety Endpoint: F1 (3 shared claims), F3 (5 shared claims), F6 (1 shared claims)
- Secondary endpoint: Local Progression Disease (Local PD): F6 (1 shared claims)
- Population and setting: F1 (2 shared claims), F2 (1 shared claims), F3 (1 shared claims), F4 (8 shared claims), F5 (4 shared claims), F6 (1 shared claims)
- The comparison: F1 (6 shared claims), F2 (1 shared claims), F3 (1 shared claims), F4 (2 shared claims), F5 (6 shared claims), F6 (2 shared claims)
- Safety and tolerability: F1 (3 shared claims), F3 (5 shared claims), F6 (1 shared claims)
- Design and conduct: F1 (6 shared claims), F3 (1 shared claims), F4 (1 shared claims), F5 (1 shared claims), F6 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F5. Radiation inclusion is valued, but adjuvant intent and the pre-MDT dose remain separate questions

An X poster asks what a pembrolizumab dose given before surgery or stereotactic radiotherapy contributes in PE-PE.

Source: X thread, 2026-10-25.

### F6. Distant relapse supports a systemic-treatment rationale, while technical details remain important to interpretation

An X poster asks about radiotherapy dosing, site-specific information and local versus distant recurrence in PE-PE. The thread also asks about previous systemic treatment and the timing and extent of the initial metastatic presentation.

Source: X thread, 2026-10-26.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 35 | Paid |
| Trial aspects mapped | 13 | Free |
| Sources with links | 14 | Counts free |
| Speaker attribution for cited voices | 14 | Paid |

## Trial aspects

13 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Relapsed Free Survival (RFS) | discussed | 10 | 8 |
| Secondary endpoint: Distant Relapsed Free Survival (Distant RFS) | discussed | 3 | 2 |
| Secondary endpoint: Overall Survival (OS) | discussed | 2 | 2 |
| Secondary endpoint: Safety Endpoint | discussed | 5 | 5 |
| Secondary endpoint: Local Progression Disease (Local PD) | discussed | 1 | 1 |
| Population and setting | discussed | 11 | 6 |
| The comparison | discussed | 15 | 7 |
| Safety and tolerability | discussed | 5 | 5 |
| Design and conduct | discussed | 9 | 4 |
| Selection for systemic-treatment deferral | discussed | 2 | 2 |
| M1 NED precedent and the relevance of later recurrence | discussed | 4 | 3 |
| What the comparison does not prove: MDT benefit, synergy and quality of life | discussed | 3 | 1 |
| Local-treatment technique and prior disease history needed for interpretation | discussed | 3 | 2 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 25 | 11 |
| Bluesky threads | 2 | 1 |
| LinkedIn posts | 1 | 1 |
| X videos | 2 | 0 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2023-04-05 to 2026-10-29
- Cited window: 2023-04-05 to 2026-10-28
- Retrieved: 2026-10-29

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer. (The PE-PE Study).
- Registry: NCT05578664 (https://clinicaltrials.gov/study/NCT05578664)
- Study IDs: PE-PE
- Sponsor: Consorzio Oncotech
- Design: Phase 2 · interventional, randomized, parallel, phase2
- Status: Active, not recruiting
- Enrollment: 85 (actual)
- Start: 2023-03-14 (actual)
- Primary completion: 2028-03 (estimated)
- Primary endpoint: Relapsed Free Survival (RFS) (24 months)
- Intervention: Pembrolizumab injection plus metastasis directed treatment (surgery or RT) (drug)
- Intervention: Tumor resection or RT (other)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 17 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The report describes public discussion in the sources reviewed for this edition, not all HCP views or the frequency of any view. Cross-platform copies and reposts do not establish additional independent endorsements.
- An audiovisual item's wording was available only from an initial transcript and could not be checked against a fuller transcript.
- No full protocol document, exact-trial results publication or exact regulatory label for the pembrolizumab-plus-MDT regimen is included. The reported outcomes remain presentation-based commentary, and comments about indications do not establish regulatory status.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The endpoint terminology differs between a speaker's PFS wording and the registry's RFS wording. Another speaker's eight-cycle description also differs from the nine-cycle regimen described by the registry and another speaker; neither discrepancy is silently resolved.
- Post dates identify when statements were shared, not when a session or readout occurred, and do not demonstrate a change in a speaker's opinion.
- Not yet captured in this edition: a view on oligometastatic eligibility thresholds and relapse-free survival with pembrolizumab plus metastasis-directed treatment.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-29: current edition, corrected 2026-10-29
  - Correction 2026-10-29: Corrected to match the delivered report: the limitations; the sample findings. The page names the trial's tested drugs (pembrolizumab) and indication (oligometastatic renal cell carcinoma).

Last checked for new commentary 2026-10-29. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (35 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (13 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/pe-pe-nct05578664
- Agents: POST https://www.erudio.com/api/orders with {"report": "pe-pe-nct05578664", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=pe-pe-05578664

## Cite

Erudio Health. PE-PE (NCT05578664): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/pe-pe-nct05578664

## Machine access

- JSON: https://www.erudio.com/reports/pe-pe-nct05578664.json
- Markdown: https://www.erudio.com/reports/pe-pe-nct05578664.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "pe-pe-05578664"}`